Small volume resuscitation with albumin in intensive care (SWIPE)
Research type
Research Study
Full title
A Pilot, Randomised, Unblinded, Feasibility, Safety, Biochemical and Physiological Efficacy Study of 20% vs 5% Human Albumin Solution for Fluid Bolus Therapy in Critically Ill Adults
IRAS ID
197247
Contact name
Jonathan Bannard-Smith
Contact email
Sponsor organisation
Manchester University NHS Foundation Trust
Eudract number
2016-001940-20
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
Administration of fluids directly into a vein is commonly used to treat low blood pressure in critically ill patients. This treatment is known as 'fluid resuscitation' and aims to increase the circulating blood volume to improve blood flow to body organs. Prolonged fluid resuscitation may, however, lead to fluid building up in the tissues, which can cause organ damage and even reduce the chances of patients surviving their illness.
Albumin is a natural part of human blood. Two different albumin-containing fluids are legally licensed for use as fluid resuscitation; a 5% solution and a more concentrated 20% solution. Theoretically, the more concentrated 20% albumin solution can accomplish the same volume expansion effect as the 5% solution using only one fifth of the administered volume. If we could provide fluid resuscitation to patients using the lowest volume of fluid possible this may reduce the chances of organ damage, increase the speed of recovery from critical illness and potentially improve patient survival.
The aim of this study is to test whether fluid resuscitation with 20% albumin solution reduces the accumulation of fluid and organ damage in critically ill patients as compared to fluid resuscitation with the 5% albumin solution. The study will involve 400 adult participants. Adult patients will be enrolled to the study from intensive care units at The Austin Hospital in Melbourne, Australia, The Flinders Medical Centre in Adelaide, Australia and Manchester Royal Infirmary in Manchester, United Kingdom. We intend to publish our findings of this study in peer-reviewed critical care journals. Our results may support to move toward a larger international multi-centred randomised-crontolled trial. In Australia this study is funded by the Austin Hospital Special Purpose Fund, in the United Kingdom it is funded by CSL Behring.
REC name
Yorkshire & The Humber - Sheffield Research Ethics Committee
REC reference
16/YH/0349
Date of REC Opinion
11 Oct 2016
REC opinion
Further Information Favourable Opinion